Application No.	Drug	Applicant
ANDA 62–455	Polymyxin B Sulfate, USP (for prescription compounding)	Do.
ANDA 62–456	Bacitracin Powder, USP (for prescription compounding)	Do.
ANDA 74–084	Diltiazem Hydrochloride Tablets USP, 30 mg and 60 mg	Novopharm N.C., Inc., agent for Novopharm Ltd., 4700 Novopharm Blvd., Wilson, NC 27893.
ANDA 74–511	SULSTER (Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution, 10%/eq. 0.23% phosphate)	Taylor Pharmaceuticals (an Akorn Co.), 150 South Wyckles Rd., P.O. Box 1220, Decatur, IL 62525–1220.
ANDA 80–025	Sulf-10 (Sulfacetamide Sodium Ophthalmic Solution, USP) 10%	Ciba Vision, 11460 Johns Creek Pkwy., Duluth, GA 30097–1556.
ANDA 83–648	Meprotabs (Meprobamate Tablets USP, 400 mg)	Wallace Laboratories, Division of Carter-Wallace, Inc., Half Acre Rd., P.O. Box 1001, Cranberry, NJ 08512–0181.
ANDA 85–136	Methocarbamol Tablets USP (750 mg)	Forest Laboratories, Inc., 909 Third Ave., New York, NY 10022–4731.
ANDA 85–137	Methocarbamaol Tablets USP (500 mg)	Inwood Laboratories, Inc., 909 Third Ave., New York, NY 10022–4731.
ANDA 86–228	Nitroglycerin Extended-release Capsules (2.5 mg)	Geneva Pharmaceuticals, Inc., 2655 West Midway Blvd., P.O. Box 446, Broomfield, CO 80038–0446.
ANDA 86–230	Nitroglycerin Extended-release Capsules (6.5 mg)	Do.
ANDA 87–797	Triamcinolone Acetonide Cream USP, 0.025%	Alpharma USPD, Inc., 333 Cassell Dr., suite 3500, Baltimore, MD 21224.
ANDA 88–220	Nitroglycerin Extended-release Capsules (9 mg)	Geneva Pharmaceuticals, Inc.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective September 25, 1998.

Dated: September 14, 1998.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 98–25713 Filed 9–24–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0503]

Agency Information Collection Activities; Announcement of OMB Approval; New Animal Drug Application (NADA), Form FDA 356 V, 21 CFR Part 514

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''New Animal Drug Application (NADA), Form FDA 356 V, 21 CFR Part 514'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT: Denver Presley, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1472.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of June 9, 1998 (63 FR 31505), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the PRA (44 U.S.C. 3507). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0032. The approval expires on July 31, 2001.

Dated: September 17, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–25642 Filed 9–24–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Water Soluble Drugs and Methods of Preparing Same

DK Ho et al. (SAIC/NCI)
Serial No. 60/093,284 filed 17 Jul 98
Licensing Contact: Girish Barua, 301/496–7056, ext. 263

Many potential drugs of cancer chemotherapy intended for parenteral administration have been abandoned because the active ingredient is slightly soluble or water-insoluble. Various methods have been developed to allow these drugs to be dissolved in water; however, these methods can be complex and have negative impacts resulting from the use of cosolvents and complexing agents. The present invention addresses these problems by providing a method of producing water-soluble analogues of water-insoluble drugs through derivatization and conjugation with a polar moiety via a thiol ether bond with a